References
- Cibas ES , AliSZ. The Bethesda system for reporting thyroid cytopathology. Thyroid19, 1159–1165 (2009).
- Hambleton C , KandilE. Appropriate and accurate diagnosis of thyroid nodules: a review of thyroid fine-needle aspiration. Int. J. Clin. Exp. Med.6(6), 413–422 (2013).
- Rabaglia JL , KabbaniW, WallaceLet al. Effect of the Bethesda system of reporting thyroid cytopathology on thyroidectomy rates and malignancy risk in cytologically indeterminate lesions. J. Surg.148(6), 1267–1273 (2010).
- Broome JT , CateF, SolorzanoCC. Utilization and impact of repeat biopsy for follicular lesion/atypia of undetermined significance. World J. Surg.38(3), 628–633 (2014).
- Ho AS , SartiEE, JainKSet al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid24(5), 832–839 (2014).
- Alexander EK , KennedyGC, BalochZWet al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med.367(8), 705–715 (2012).
- Alexander EK , SchorrM, KlopperJet al. Multicenter clinical experience with the Afirma gene expression classifier. J. Clin. Endocrinol. Metab.99(1), 119–125 (2014).
- Dedhia PH , RubioGA, CohenMS, MillerBS, GaugerPG, HughesDT. Potential effects of molecular testing of indeterminate thyroid nodule fine needle aspiration biopsy on thyroidectomy volume. World J. Surg.38(3), 634–638 (2014).